What Your Insulin Pump's Day-to-Day Patterns Can Tell You About Control
A new analysis of hybrid closed-loop systems reveals that how much an insulin pump's automated corrections vary from day to day may be just as important as the average amount of insulin it's delivering.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- The Automated Correction Index (ACI) measures what percentage of your insulin boluses are automatically delivered by your pump versus manually entered by you.
- Day-to-day variability in ACI—how much this percentage changes from one day to the next—appears linked to better time in range.
- Higher variability in automated corrections was associated with more time in the 70–180 mg/dL range and less time running high.
- This finding suggests that looking at patterns over time, not just average settings, may help explain how well a hybrid closed-loop system is working for you.
- Researchers suggest this metric could give doctors and patients a new lens for understanding and fine-tuning their pump behavior.
Understanding the Automated Correction Index
Modern hybrid closed-loop insulin pumps—like the MiniMed 780G—use algorithms to make automatic insulin adjustments throughout the day. The Automated Correction Index, or ACI, is a way to measure how much of your total insulin is being delivered automatically by the pump versus how much you're manually entering yourself.
Until now, researchers and clinicians mostly looked at the *average* ACI: the mean percentage of automated corrections over time. But a new study suggests that focusing only on that average might miss part of the story.
What Happens When Day-to-Day Variability Matters
Researchers at multiple diabetes centers studied 330 people with Type 1 diabetes using the MiniMed 780G system. They looked not just at average ACI, but at how much the ACI *varied* from day to day over a 30-day period—a metric they call ACI-V%.
They found something unexpected: people with higher day-to-day variability in their ACI actually had better glucose control. Specifically, higher ACI-V% was linked to more time in the target glucose range (70–180 mg/dL) and less time running high. There was no meaningful connection between ACI-V% and time spent low, however.
The data also showed that ACI-V% and average ACI move in opposite directions: when the average automated correction amount was lower, the day-to-day variability tended to be higher.
A Possible Threshold for Success
The researchers identified a potential benchmark: patients whose ACI varied by 32.6% or more from day to day were more likely to achieve the common target of spending at least 70% of their time in range. This doesn't mean the threshold is a guarantee—the sensitivity and specificity of this cutoff were moderate—but it suggests a possible starting point for clinical conversations.
It's important to note that this is early, exploratory research. The threshold and its predictive strength will need to be confirmed in other studies before it could be used as a clinical tool.
What This Means for You
If you use a hybrid closed-loop system, this research suggests that the day-to-day rhythm of your pump's behavior may reveal something useful about how well it's working for you—something different from just looking at average settings.
Your healthcare team may eventually use ACI-V% as part of understanding whether your pump algorithm is functioning optimally. For now, this finding offers a reminder that glucose management is never exactly the same from one day to the next—and that variability in how your pump responds isn't necessarily a problem. It might even be a sign that your system is adapting well to your changing needs.
If you're curious about whether this metric might apply to your own system, it's a great question to discuss with your diabetes care team.
Evidence label
Source: Diabetes research and clinical practice. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Living With T1DWhat We're Learning About Diabetic Ketoacidosis in Type 1 Diabetes: A French StudyPubMed indexed literature
- Living With T1DCorrection to "The Use of an Automated Insulin Delivery System Is Associated With a Reduction in Diabetes Distress and Improvement in Quality of Life in People With Type 1 Diabetes".PubMed indexed literature
- Living With T1DA New Class of Biologics Could Change How We Treat Type 1 DiabetesPubMed indexed literature
- Living With T1DMenopause and Type 1 Diabetes: What Women Need to KnowPubMed indexed literature
- Living With T1DThe Promise and Challenge of Oral Insulin: Where the Research StandsPubMed indexed literature
- Living With T1DYour Glucose Range May Not Be the Guideline Range—And That's Worth UnderstandingPubMed indexed literature